{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Finerenone", "query": { "intervention": "Finerenone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Finerenone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T10:33:16.659Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05196035", "title": "A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease", "Proteinuria" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 219, "start_date": "2022-03-28", "completion_date": "2027-05-10", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 10, "location_summary": "Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05196035" }, { "nct_id": "NCT06143566", "title": "Polypill for Prevention of Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Type 2 Diabetes", "High Blood Pressure" ], "interventions": [ { "name": "Polypill", "type": "DRUG" }, { "name": "Combined prescription of the individual medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 200, "start_date": "2024-03-11", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06143566" }, { "nct_id": "NCT02545049", "title": "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Kidney Disease" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7352, "start_date": "2015-09-17", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2022-04-15", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 173, "location_summary": "Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02545049" }, { "nct_id": "NCT07192952", "title": "A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Left Ventricular Systolic Dysfunction", "Heart Failure (Pediatric)" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY94-8862)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 117, "start_date": "2026-06-01", "completion_date": "2030-12-30", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 22, "location_summary": "Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07192952" }, { "nct_id": "NCT04435626", "title": "Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 6016, "start_date": "2020-09-14", "completion_date": "2024-06-14", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 107, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435626" }, { "nct_id": "NCT01807221", "title": "Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Inspra (eplerenone)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1066, "start_date": "2013-06-17", "completion_date": "2014-12-09", "has_results": true, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807221" }, { "nct_id": "NCT05703880", "title": "An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY948862)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15948, "start_date": "2023-06-01", "completion_date": "2024-10-01", "has_results": false, "last_update_posted_date": "2024-10-18", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Eden Prairie, Minnesota", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05703880" }, { "nct_id": "NCT07547878", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Lotensin", "type": "DRUG" }, { "name": "Capoten", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Monopril", "type": "DRUG" }, { "name": "Lisinopril", "type": "DRUG" }, { "name": "Univasc", "type": "DRUG" }, { "name": "Aceon", "type": "DRUG" }, { "name": "Accupril", "type": "DRUG" }, { "name": "Altace", "type": "DRUG" }, { "name": "Mavik", "type": "DRUG" }, { "name": "Edarbi", "type": "DRUG" }, { "name": "Atacand", "type": "DRUG" }, { "name": "Avapro", "type": "DRUG" }, { "name": "Cozaar", "type": "DRUG" }, { "name": "Benicar", "type": "DRUG" }, { "name": "Micardis", "type": "DRUG" }, { "name": "Diovan", "type": "DRUG" }, { "name": "Invokana", "type": "DRUG" }, { "name": "Farxiga", "type": "DRUG" }, { "name": "Jardiance", "type": "DRUG" }, { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Brenzavvy", "type": "DRUG" }, { "name": "Sotagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 64, "start_date": "2026-04-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "nct_id": "NCT06024746", "title": "A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colorado Prevention Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2024-07-09", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 33, "location_summary": "Fairhope, Alabama • El Centro, California • Sacramento, California + 30 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "El Centro", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Van Nuys", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06024746" }, { "nct_id": "NCT05526157", "title": "An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY 948862)", "type": "DRUG" }, { "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)", "type": "DRUG" }, { "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)", "type": "DRUG" }, { "name": "Steroidal mineral corticoid receptor antagonists (sMRA)", "type": "DRUG" }, { "name": "Non-steroidal mineral corticoid receptor antagonists (nsMRA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50000, "start_date": "2022-10-01", "completion_date": "2024-09-05", "has_results": false, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-02T10:33:16.659Z", "location_count": 1, "location_summary": "Eden Prairie, Minnesota", "locations": [ { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05526157" } ] }